Adam Elhofy
Vice President, Research COUR Pharma
Dr. Elhofy has more than 25 years of scientific research experience in immunology, neuroscience, and oncology, with 20 scientific publications in peer-reviewed journals. Before joining COUR, Dr. Elhofy was the Chief Science Officer at Essential Pharmaceuticals, LLC, where he invented and patented the core technology for their Cell-Ess line of products, which can be used in a broad range of applications, including, but not limited to, bioproduction and primary research. He was also a Principal Investigator at a nanoparticle spin out from Argonne National Laboratories to treat skin-related autoimmune diseases. Dr. Elhofy was a Research Associate Professor at Northwestern Medical School, where he was funded with 2 multiple sclerosis training grants.
Seminars
- Explore in-depth clinical analyses of PBC including UK-PBC scoring, ALBI/GLOBE metrics, and emerging biomarkers to understand how tolerance influences disease prognosis
- Highlight responder outcomes, including responder-rate evaluation and respondercurve profiling following tolerance induction
- Delve into how these findings support translation into Myasthenia Gravis (MG), outlining clinical implications and future development strategy
